KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to $15.8 million.

  • CRISPR Therapeutics AG's Current Deferred Revenue rose 31016.91% to $15.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $15.8 million, marking a year-over-year increase of 31016.91%. This contributed to the annual value of $15.8 million for FY2025, which is 31016.91% up from last year.
  • CRISPR Therapeutics AG's Current Deferred Revenue amounted to $15.8 million in Q4 2025, which was up 31016.91% from $1.3 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Current Deferred Revenue registered a high of $15.8 million during Q4 2025, and its lowest value of $1.3 million during Q3 2025.
  • For the 5-year period, CRISPR Therapeutics AG's Current Deferred Revenue averaged around $5.7 million, with its median value being $3.8 million (2024).
  • Over the last 5 years, CRISPR Therapeutics AG's Current Deferred Revenue had its largest YoY gain of 31016.91% in 2025, and its largest YoY loss of 7111.31% in 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Current Deferred Revenue (Quarter) stood at $12.3 million in 2021, then changed by 0.0% to $12.3 million in 2022, then changed by 0.0% to $12.3 million in 2023, then plummeted by 68.74% to $3.8 million in 2024, then soared by 310.17% to $15.8 million in 2025.
  • Its last three reported values are $15.8 million in Q4 2025, $1.3 million for Q3 2025, and $2.1 million during Q2 2025.